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Glossary of abbreviations:  
IPF: Interstitial Pulmonary Fibrosis, COPD: Chronic Obstructive Pulmonary Disease, NYHA: 
New York Heart Association, FEV: Forced Expiratory Volume, DLCO: diffusing capacity of 
lung for carbon monoxide, LAS: Lung Allocation Score, CNI: Calcineurin inhibitors 
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Section 1: Introduction 
Lung transplantation provides a life-saving therapy for patients with end-stage pulmonary 
disease. Two of the three most common indications for lung transplantation include idiopathic 
pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). After these two 
disease processes comes cystic fibrosis, as the third most common indication for lung 
transplantation in both adult and pediatric patient populations. In all three disease states, 
oxygenation of blood can decrease and cause symptomatic end stage lung disease and an oxygen 
requirement in patients. Patients begin to be considered for lung transplantation when life 
expectancy is not predicted to exceed 24-36 months despite optimal and maximal medical 
management and they have class III or IV New York Heart Association (NYHA) symptoms. 
Specifically for patients with COPD, FEV1 can help determine when a patient should be referred 
for transplant. FEV1 of less than 30% predicted is associated with a 60-80% two year survival 
rate, and hence, transplation should be offered to COPD patients with an FEV1 substantially less 
than 30% predicted. In patients with idiopathic pulmonary fibrosis, the diffusing capacity of lung 
for carbon monoxide (DLCO) is a parameter that is useful in predicting the survival of patients 
with restrictive disease; a DLCO of less than 35-39% is associated with a higher risk of 
mortality. In the era of the Lung Allocation Score (LAS), transplantation for fibrotic lung disease 
is becoming more common. In 2009 more than 3,200 lung transplantation were performed 
worldwide in accordance with the LAS. The LAS is used to prioritize waiting list candidates 
based on a combination of waitlist urgency and post-transplant survival. Waitlist urgency is 
defined as what is expected to happen to a candidate, given his or her characteristics, in the next 
year if he or she doesn’t receive a transplant. Post-transplant survival represents what is expected 
to happen to a candidate, given his or her characteristics, in the first year after a transplant if he 
or she does receive the transplant. Lung transplant outcomes have greatly improved since the 
first lung transplant in 1983 [1], but significant morbidity still results from long-term 
immunosuppressive therapy needed to prevent graft rejection. Currently the national average 1 
month graft survival rate is >95%, with a 1 year average of 83%, and 3 year average of 64%. 
Immunosuppression reduces the natural antitumor immune response, predisposing transplant 
recipients to an increased risk for malignancies [2]. At least one malignancy is diagnosed in 13% 
of 5-year survivors and in 28% of 10-year survivors. There is compelling evidence to support the 
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notion that immunogenic tumors, in murine models and cancer patients, can be rejected by the 
immune system under optimum conditions for activating adaptive and nonadaptive antitumor 
immune responses. In the last decade, there has been an increase in the development of lung 
cancer in lung transplant recipients [3]. This increase may be due to a longer survival time for 
transplant recipients [4] and an increased number of patients receiving transplants for COPD and 
IPF [3] at an older age. Twenty percent of lung transplants performed since 2001 have been in 
recipients older than 59. In the general population, crossing the age of 60 years doubles the risk 
for lung cancer.  In addition, compared to transplants performed between 1989-1996, during 
which there was a 40% survival rate at 5 years post-transplant, survival for lung transplant 
recipients at a 5 year time point increased to 60% for patients who received transplants between 
1997-2007. A review of the Scientific Registry of Transplant Recipients found an elevated 
standardized incidence ratio of 6.13 for the development of lung cancer in lung transplant 
recipients, higher than any other solid organ recipient cohort [5]. The overall cancer risk among 
175,732 solid organ recipients was 10,656 cases. The most common malignancy with elevated 
risk was non-Hodgkin lymphoma. After lung transplant recipients, kidney, liver, and heart 
transplant recipients had the greatest risk for diverse infection-related and unrelated cancers. The 
higher incidence of lung cancer in lung transplant recipients may be partially explained by the 
fact that COPD and IPF, both conditions with a high prevalence of smokers are some of the most 
common indications for lung transplant. There is an increased risk of lung cancer in COPD, and 
whether obstructive lung disease itself is an independent risk factor for lung cancer is subject to 
debate [6]. Further, IPF has been linked to an increased risk for the development of lung cancer, 
17% in one autopsy series [7]. This reflects a greater prevalence than in patients without IPF and 
seems to persist even when smoking habits are considered [8]. Finally and importantly, 
immunosuppressive regimens in lung transplant are substantially more aggressive than in other 
solid organ transplant, since the incidence of acute and chronic organ rejection is markedly 
higher, representing an important risk factor for development of malignancy post-transplant, 
through different mechanisms [9-13]. Immunosuppresive drugs also may act directly on 
carcinogenic pathways. Calcineurin inhibitors (CNIs), cyclosporine and tacrolimus, may enhance 
tumor progression by inhibition of DNA repair, antiapoptotic effect in damaged cells, and 
inhibition of cell adhesion favoring cell migration and metastatic spread. In addition, 
azathioprine may promote microsatellite DNA instability. Newer agents, such as mycophenolate 
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and mTOR inhibitors demonstrate the ability to reduce tumor progression. Patient’s undergoing 
unilateral lung transplants are placed at higher risks for malignancy as the remaining lung, 
formerly exposed to inhaled risk factors, is not introduced to the stress of immunosuppression. 
While the increased risk for cancer post-lung transplant has been documented, there are only a 
few studies presenting data detailing the discovery of bronchogenic carcinoma in the explanted 
lung at the time of surgery [14-16]. One study reported 2 cases of stage I adenocarcinoma, both 
less than 1 cm, incidentally found in the pneumonectomy specimen at the time of single lung 
transplantation. The remainder of each lung showed no evidence of adenocarcinoma and all 
lymph nodes were negative. Work-ups for an occult malignancy before and after surgery were 
negative in both cases. Further reports include a recommended work-up after the discovery of the 
incidental lung cancer, involving mediastinal staging with mediastinoscopy, with the back 
thought of potential adjuvant therapy. Tapering immunosuppression during the initial post 
transplant period was not addressed. Such reports indicate a 5-year survival rate for patients with 
cancer in the explanted lung ranging from 25-51%, depending on pTNM stage. Survival thus far 
appears to be more favorable fore patients with stage I disease (51% at 5 years) compared with 
stages II and III (14%). The majority of patients with stage II or III carcinoma experienced 
recurrence and died within the first year of transplantation.  
A better understanding of the prevalence of lung cancer and the definition of at-risk populations 
in patients under going lung transplantation could help to identify methods to improve transplant 
safety and the prognoses for patients who develop bronchogenic carcinoma. It is unclear whether 
certain chemotherapy or immunosuppression regimens can best decrease tumor burden and the 
risk for metastatic disease in such patients. In addition, it is unclear who the patients are who are 
harboring lung cancers incidentally found on pathology reviews from lung transplantations. To 
this end, we conducted a retrospective study on both the discovery of lung cancer in explanted 
lungs and the development of de novo bronchogenic carcinoma post-transplant at Brigham and 
Women’s Hospital. 
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Section 2: Methods 
We conducted a retrospective chart review of all patients who underwent a lung transplant at 
Brigham and Women’s Hospital (BWH) between January 1990 and June 2012. The study was 
reviewed and approved by BWH institutional review board (Protocol Number 2011-P-
002392/1). 
In the study period a total of 457 subjects underwent lung transplant at BWH. Of these subjects, 
5 received a retransplant of an already transplanted lung, bringing the total number of lung 
transplant surgeries to 462. In these 5 cases, native lungs were counted as explants. Transplanted 
lungs were counted both as a transplant and explants. 4 patients were transplanted for chronic 
rejection and one patient was retransplanted for recurrent acute rejection. 
Lung transplant recipients in whom cancer was identified in the explanted lung at the time of 
transplant, or in whom lung cancer was identified post-transplant either in the native lung or in 
the allograft, were identified from Brigham and Women’s Hospital’s computerized hospital 
records and lung transplant surgery database. Histology slides from all identified cases of 
malignancy were reviewed by a pulmonary pathologist (RP) to confirm the cancer diagnosis. 
Cases of post-transplant lymphoproliferative disorder were excluded from the post transplant 
lung cancer analysis. 
During the study period, the policy at BWH required all patients listed for lung transplantation to 
keep computed tomography (CT) scans of the chest updated yearly prior to lung transplant. 
Suspicious findings on these scans were evaluated according to published guidelines [17], and 
any malignant findings seen on a biopsy, or a positive fludeoxyglucose positron emission 
tomography (FDG-PET) when biopsies are deemed unsafe because of the patient’s respiratory 
compromise resulted in the removal of the subject from the lung transplant eligibility list. Of the 
patients who were found to have carcinoma in the explanted lung, only one was transplanted 
prior to the policy of yearly CT scans. The CT scan in this case was performed 21 months prior 
to transplant and had not shown any evidence of malignancy. 
Donors with a greater than 20 pack year history of smoking were screened with chest CT scan 
prior to organ acceptance. Evidence of suspicious nodules on donor imaging or gross inspection 
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at the time of procurement led to either biopsy with frozen section analysis and/or exclusion 
from lung donation. 
Post-transplant, subjects received immunosuppression consisting of standard therapy at the time 
of transplant. In 2001 our program transitioned from cyclosporine A to tacrolimus (levels 
adjusted to 8-12 ng/ml in the first year post-transplant, and 6-8 ng/ml thereafter), and from 
azathioprine to mycophenolate (1 gm twice a day), as standard de novo immune suppression. In 
2008, our program substantially decreased the systemic corticosteroid dosing administered to 
recipients, and transitioned from equine antithymocyte globulin (ATG) to Rabbit ATG for 
induction. Most patients receive induction unless there is a concern for significant infectious risk. 
Per standard pathology protocol at our institution, lungs explanted at the time of transplantation 
were inflated with formalin through the bronchus for adequate fixation. The lungs were serially 
sectioned thinly in either a coronal or parasaggital plane to evaluate the parenchyma for 
pathologic processes such as the underlying lung disease, infection or malignancy. Several 
histological sections from the central and peripheral aspects of each lobe were taken, in addition 
to sections of any masses, nodules, cysts or areas of consolidation. Standard sections of the 
bronchial and vascular resection margins as well as samples of hilar and intrapulmonary lymph 
nodes were taken. 
In addition, and depending on their clinical status, subjects underwent serial surveillance 
bronchoscopies at 1 week and 1, 3, 6, and 12 months post-transplant, with transbronchial 
biopsies taken at 1, 3, 6, and 12 months to evaluate for acute allograft rejection. 
 
Statistical analysis 
Results are expressed as mean SD of the mean unless otherwise specified. A t-test was 
performed to calculate difference in means. A Chi square test was performed to calculate 
difference of proportion. Statistical analysis was performed using Graphpad Prism (GraphPad 
Software Inc, La Jolla, CA). A p < 0.05 was used as the cutoff to determine statistical 
significance. 
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Section 3: Results 
The mean age of the recipients was 49.13 years. Of the 462 cases, 214 were bilateral lung 
transplants. The three most common causes for lung transplantation were COPD, IPF, and CF 
(Table 1). Twenty three percent of subjects with IPF and 10% of subjects with COPD received 
bilateral transplants. Recipients of lung transplant for CF were significantly younger than 
subjects with IPF or COPD (P < 0.01). 
Malignancy in the explanted lung 
Of the 462 transplant procedures performed, 6 subjects were found to have bronchogenic 
carcinoma in the explanted lung, resulting in a prevalence of 1.2% (6 out 462 procedures) (Fig. 
1, and Fig. 2A-D). All 6 subjects had been diagnosed with interstitial lung disease (ILD), 5 with 
idiopathic pulmonary fibrosis and one with sarcoidosis (Table 2). This resulted in a prevalence of 
malignancy of 4.1% (6 of 146) in the ILD population and of 4.2% in those transplanted for 
pulmonary fibrosis (5 of 117). There was no difference in the mean age of patients with 
interstitial lung disease who were diagnosed with lung cancer versus the unaffected group (p > 
0.05). All of these malignancies were identified as adenocarcinomas. 
When data were analyzed as before and after the establishment of the LAS system, we found the 
prevalence of lung cancer in the explanted lung to be 0.38% (one out of 262 patients) in the pre-
LAS period and 2.5% (5 out of 200) in the post-LAS period (p Z 0.08). 
Lung cancer post-transplant 
The prevalence of lung cancer post-lung transplant was 1.9% (9 of 462) (Fig. 1). Bronchogenic 
carcinoma occurred more frequently in single versus bilateral lung transplant recipients (2.7% 
versus 0.93% respectively; p < 0.001). In subjects transplanted for obstructive lung disease the 
prevalence was 3.3% (4 of 118 patients with COPD), compared to a prevalence of 2.7% for 
subjects transplanted for interstitial lung disease (4 of 146 patients with ILD) (p < 0.05). 
However, when comparing to patients who received lung transplant for IPF the prevalence was 
similar at 3.4% (4 of 117). One subject who was transplanted for CF developed bronchogenic 
carcinoma. 
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Of 7 recipients of single lung transplants, carcinoma was detected in the native lung in 5 cases. 
In one patient with IPF, the disease was metastatic at the time of diagnosis. Cytogenetic studies 
confirmed the tumor to be recipient derived (male donor in a female recipient). In the other case 
of a patient with COPD the tumor was metastatic at the time of diagnosis; however it was also 
confirmed to be recipient related by cytogenetic studies. 
Two recipients of bilateral lung transplants developed bronchogenic carcinoma. In one subject 
with COPD the tumor arose from the right main stem, and was thought to be recipient related. In 
one subject with cystic fibrosis, the tumor arose from the right hilum. Cytogenetic studies were 
inconclusive in determining whether the tumor was donor or recipient related. 
The time to the discovery of the lung cancer in these 9 subjects ranged from 9 months to 10 years 
post-transplant, with a mean of 28 months (Table 3). 
Of the 9 patients diagnosed with cancer post-transplant the diagnosis was established with a 
wedge resection/surgical lung biopsy in 6 cases. In 2 cases, bronchoscopy with cytology analysis 
established the diagnosis and patients were staged with a PET-scan. In one case, cancer was 
metastatic at the time of diagnosis with diffuse FDG-PET uptake and diagnosis was established 
with a bone biopsy. 
When data were examined in the pre- and post- LAS eras, we found that the prevalence of lung 
cancer post-transplant to be 1.52% (4 out of 262) in pre LAS, and 2.5% (5 out of 200) in post-
LAS (Z=0.509). 
Changes to the immunosuppressive regimen 
When cancer was discovered at the time of transplant, the diagnosis of cancer resulted in a 
change in the immunosuppressive regimen in all subjects. Mycophenolate mofetil was not 
introduced or stopped shortly after pathology results. Surveillance biopsies (12 transbronchial 
biopsies on 6 patients: range 1-4 per subject) did not show any evidence of acute rejection. 
When cancer was discovered in post-transplant followup, mycophenolate mofetil was stopped in 
5 patients. In 3 patients, the disease was advanced and subjects had elected not to pursue 
chemotherapy no changes were made to their immunosuppressive regimen. 
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In all patients tacrolimus levels were kept at the low-end of the desired range according to 
individual patient years after transplant. 
Therapy and outcome 
Six patients were diagnosed with lung cancer at the time of transplant, 2 had early stage disease 
(stage I), and surgery was considered curative. One of these subjects’ remains alive at 36 months 
post-transplant, and the other died 6 months after transplant of sepsis and kidney failure. The 
remaining 4 subjects had advanced disease with lymph node involvement at the time of surgery; 
3 of these subjects received platinum based chemotherapy and one subject declined therapy and 
passed away within 7 months of transplant. All four patients with advanced disease had evidence 
of metastasis at the time of their death. The median survival of these 4 patients was 16.5 months 
(range of 7-25 months). 
Nine patients were diagnosed with lung cancer after transplantation, and 4 had early stage 
disease (stage I). Three patients underwent lung resection for curable disease; one subject 
remains alive 48 months after resection, one died of unrelated causes 46 months after the cancer 
diagnosis, and one subject developed recurrent malignancy in the same lung, underwent radiation 
therapy and died 18 months later from causes directly related to the malignancy. One patient had 
a lesion potentially curable with surgical resection, however he was suffering from advanced 
chronic allograft dysfunction and he underwent stereotactic body radiation therapy (SBRT); he 
remains alive 8 months after the diagnosis. Subjects with stage I lung cancer had a median 
survival of 32 months (range of 8-48 months). 
Five patients had advanced disease (non-stage I) at the time of diagnosis. Four patients died of 
their malignancy and one patient remains alive 6 months after the diagnosis. Therapy was 
tailored to the patients’ overall functional status and respiratory conditions. Three patients had 
metastatic disease at the time of diagnosis and elected to receive comfort measures. One subject 
was found to have extensive disease at the time of surgery, and one subject had advanced disease 
at the time of diagnosis and underwent chemotherapy and radiation therapy. Both of these 
subjects remain alive at 8 and 6 months respectively. The median survival of patients with 
advanced stage lung cancer after transplant was 4 months (range 0.5-7 months). 
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There was no statistically significant difference in survival comparing subjects diagnosed at the 
time of transplant to those who were diagnosed in the post-transplant period (Fig. 3A). Since 
time of diagnosis (at the time of transplant or in post-transplant follow-up) did not result in 
differences in outcome, we compared all patients diagnosed with stage I lung cancer regardless 
of time of diagnosis, to patients who had more advanced lung cancer. Subjects with stage I 
disease had a significantly greater median survival of 27 months (range 6-48 months), as 
compared to 5 months (range 0.5-25 months) for all other stages (Fig. 3B). 
Section 4: Discussion 
This study reports on the prevalence of and survival after lung cancer diagnosis in explanted 
lungs at the time of transplant and on the development of lung cancer post-transplant. We also 
report outcomes of lung cancer in our patient population and show that patients with limited 
disease at the time of diagnosis have a significantly better outcome than those with more 
advanced disease, though still shorter than that of stage I disease in the general population [18]. 
To our knowledge this is the first study to report on the prevalence and outcome of lung cancer 
in explanted lungs and post-transplant development of lung cancer in the same population. 
At our institution, 1.2% of patients undergoing lung transplantation are found to have lung 
cancer in their explanted lung despite aggressive screening and surveillance. Our findings are 
consistent with limited prior reports of lung cancer prevalence in this population. Previous 
reports have shown a prevalence of 2% [15] and 0.7% [16]. A multinational study of 8000 lung 
transplants showed that the prevalence of lung cancer in the explanted lung was 0.9%, but this 
study included a number of patients who received a lung transplant for bronchioloalveolar carci- 
noma. The prevalence was 0.5% when only patients whose cancer was discovered incidentally in 
the explanted lungs were included [19]. In this study, patients who did not have any lymph node 
involvement at the time of transplant had a 51% five-year survival rate, leading the authors to 
suggest that lung transplant could be a therapy for early stage lung cancer [19]. While the 
prevalence in our study was similar to other published reports, it represents an under 
representation of the real prevalence of lung cancer in patients with end-stage lung disease, given 
that patients with known malignancy are excluded from lung transplantation in our program. 
Interestingly, all cases of lung cancer in the explanted lung in our series occurred in patients with 
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end-stage fibrotic lung disease. Previous reports have shown a higher prevalence of malignancy 
in patients with obstructive lung disease [15,19]. It is possible that serial yearly CT scans of 
patients prior to transplant results in easier detection of nodules in patients with COPD than in 
ILD patients, whose islands of tumor cells may be difficult or impossible to detect 
radiographically if they are present in areas of fibrosis. The detection of these tumor foci is 
further complicated by the fact that FDG-PET scans are often positive in fibrotic lung diseases 
even in the absence of malignancy [20]. It is also likely that the change to LAS based listing in 
2005 contributed to this pattern, since patients with fibrotic lung disease have decreased wait-list 
time and therefore less likely to be diagnosed with a malignancy. 
Post-transplant 1.9% of transplant recipients develop de novo bronchogenic carcinoma. Most 
cases were detected in the native lung of single lung transplant recipients. Although we are 
limited by the fact that this is a single center cohort, the prevalence we found of post-transplant 
malignancy is in keeping with the most recent published literature [21,22], and is likely reliable 
given the aggressive follow-up and screening that is applied to lung transplant recipients. These 
findings are also consistent with previous reports showing that single lung transplant is 
associated with higher risk of development of lung cancer [23]. 
Similar to other reports, despite close follow-up of lung transplant recipients, most lung 
transplant recipients with lung cancer are diagnosed at a fairly advanced stage [24,25]. Patients 
with early stage disease had significantly better survival than patients with advanced disease, 
highlighting the importance of early detection. In our program, post-transplant chest radiographs 
are obtained at every clinic visit, but CT scans of the chest are performed as clinically indicated. 
Considering the evidence showing that CT scan screening for lung cancer in high risk groups is 
an effective strategy to decrease mortality from lung cancer [26], studies investigating the 
benefits of this strategy in a cohort of lung transplant recipients are needed. 
Evidence suggests that immunosuppression is related to an increased incidence of malignancy in 
solid organ transplant recipients [5]. In line with other studies [24], in our series when lung 
transplant recipients were diagnosed with lung tumors, their immunosuppressive regimen was 
modified; most commonly mycophenolate mofetil was stopped. Removing this purine synthesis 
inhibitor may aid the body launching a more robust antitumor response against the lung cancer 
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by allowing for greater lymphocyte proliferation. CellCept was often removed in those cases 
where cancer was progressing more rapidly. There is a paucity of data regarding changes of 
immunosuppressive regimens in such patients; once cancer is identified in the explanted lung, 
our data indicates that stopping mycophenolate did not result in an increased incidence of acute 
allograft rejection. Other investigators have suggested that once a malignancy is diagnosed after 
transplant, switching immunosuppression to inhibitors of the mammalian target of rapamycin 
(mTOR) such as sirolimus could be beneficial, with some evidence from the renal transplant 
literature suggesting a decreased incidence of solid organ malignancy [27,28]. 
There are a few limitations to our study. First, this is a single center study; second the study was 
conducted over a long period of time, with changes in standard of care of immunosuppression 
and cancer care; third, the time to follow-up for some patients is short, with some patients 
followed for less than 1 year post development of lung cancer. 
In conclusion, lung cancer in lung transplant recipients, whether identified in the explants or later 
in the follow-up period, remains rare. However, outcomes remain poor, with often times 
advanced stage disease at the time of diagnosis. Survival is better in transplant recipients 
diagnosed with stage I disease, but was still not comparable to that of the general population in 
our cohort. Strategies to identify tumors in fibrotic lung disease and in the post-transplant period 
are needed. The impact of modifying immunosuppressive therapy should be studied in larger 
cohorts. 
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